Currently under development by Viamet Pharma,VT-1161 is intended for the treatment of fungal infections in humans.
Viamet president and CEO Robert Schotzinger said in preclinical studies, VT-1161 has been shown to be one of the potent antifungal agents ever discovered against a wide range of pathogenic fungi which cause diseases such as invasive candidiasis and onychomycosis.
"However, despite its high potency, VT-1161 has also exhibited a very impressive safety and pharmacokinetic profile," Schotzinger said.